Elicio Therapeutics (ELTX) Return on Equity (2020 - 2026)

Elicio Therapeutics has reported Return on Equity for 7 years, with the latest figure at 3.86% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 424.0% year-over-year to 3.86%; the trailing twelve-month figure through Mar 2026 stood at 3.86% (down 424.0% YoY), and the FY2025 full-year result was 0.08%, up 1498.0% from the prior year.
• Return on Equity for Q1 2026 stood at 3.86%, down from 0.14% in the prior quarter.
• The five-year high for Return on Equity was 0.38% in Q1 2025, with the low at 3.86% in Q1 2026.
• Historically, Return on Equity has averaged 0.24% across 5 years, with a median of 0.0% in 2022.
• Annual changes were most pronounced in 2022 — Return on Equity surged 63 bps — and 2026, when it plunged 424 bps.
• Elicio Therapeutics' Return on Equity stood at 0.0% in 2022, then sank by 944 bps to 0.03% in 2023, then soared by 200 bps to 0.03% in 2024, then sank by 573 bps to 0.14% in 2025, then sank by 2650 bps to 3.86% in 2026.
• The last three Return on Equity figures came in at 3.86% (Q1 2026), 0.14% (Q4 2025), and 0.15% (Q3 2025), per Business Quant data.